Jerry R. Mendell
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
306
Citations
20,247
Est. group size
~4
Recurring co-author estimate
Active years
55
Publishing since 1971
Jerry R. Mendell's research focuses on inherited muscle diseases, particularly Duchenne muscular dystrophy (a genetic muscle-wasting disorder) and dysferlinopathy (a related muscle disease caused by a different gene defect). Much of the recent work involves clinical trials of gene therapies, including delandistrogene moxeparvovec, as well as natural history studies tracking disease progression using imaging and blood biomarkers. This work is clinically oriented, involving multi-site patient studies rather than laboratory-based basic science.
Publication output has fluctuated over the past decade with alternating higher and lower years (e.g., peaks in 2019, 2021, and 2023), and has declined somewhat in the most recent two years compared to the decade average.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 424PDelandistrogene moxeparvovec micro-dystrophin expression and safety in 3–4-year-olds with Duchenne muscular dystrophy in ENDEAVOR and ENVOL studies
Neuromuscular Disorders · 2025
- Modeling of Dysferlinopathy (LGMDR2) Progression
Neurology Genetics · 2025
- High‐Density Lipoprotein‐Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin‐Deficient Limb–Girdle Muscular Dystrophy Type R2
Journal of Cachexia Sarcopenia and Muscle · 2025
- 81P Minimal clinically important differences in dysferlinopathy from the 10-year, multicenter Jain Clinical Outcome Study
Neuromuscular Disorders · 2024
- 424P Micro-dystrophin expression and safety with delandistrogene moxeparvovec gene therapy for DMD in a broad population: phase 1B trial (ENDEAVOR)
Neuromuscular Disorders · 2024
- Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy
Pediatric Neurology · 2024
- P41 EMBARK, a Phase 3 trial evaluating safety and efficacy of delandistrogene moxeparvovec in DMD: study design and baseline characteristics
Neuromuscular Disorders · 2023
- P125 Quantitative MRI in upper limb muscles of patients with dysferlinopathy: 6-months and 12-months longitudinal data from the natural history Jain COS 2 project
Neuromuscular Disorders · 2023
- P42 Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy
Neuromuscular Disorders · 2023
- Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study <scp>SRP</scp>‐9001‐103 (<scp>ENDEAVOR</scp>)
Annals of Neurology · 2023
- Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
Neurotherapeutics · 2023
- Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy
Neuromuscular Disorders · 2023
- Expanding the muscle imaging spectrum in dysferlinopathy: description of an outlier population from the classical MRI pattern
Neuromuscular Disorders · 2023
- Water T2 could predict functional decline in patients with dysferlinopathy
Journal of Cachexia Sarcopenia and Muscle · 2022
- SRP-9001 for treating patients with Duchenne muscular dystrophy
2022
- Neuromuscular Disorders×26
- Neurology×11
- Journal of Neuromuscular Diseases×6
- Molecular Therapy×6
- Muscle & Nerve×5
- Louise R. Rodino‐Klapac
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Paul T. Martin
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kevin M. Flanigan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Rabi Tawil
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anne M. Connolly
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile